Loading…
Vistagen Therapeutics, Inc. is projected to rise to $0.3096 by 2027, a +20% move from its current price of $0.258. VTGN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.241 | $0.2581 | $0.2765 | +0.06% |
| Jul 14 | $0.2344 | $0.2583 | $0.2847 | +0.11% |
| Jul 15 | $0.2294 | $0.2584 | $0.2911 | +0.17% |
| Jul 16 | $0.2254 | $0.2586 | $0.2967 | +0.23% |
| Jul 17 | $0.2219 | $0.2587 | $0.3017 | +0.28% |
| Jul 18 | $0.2188 | $0.2589 | $0.3063 | +0.34% |
| Jul 19 | $0.216 | $0.259 | $0.3107 | +0.40% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.216 | $0.259 | $0.3107 | +0.40% |
| Week 2 | $0.2011 | $0.26 | $0.3363 | +0.79% |
| Week 3 | $0.1905 | $0.2611 | $0.3577 | +1.19% |
| Week 4 | $0.1822 | $0.2621 | $0.3771 | +1.59% |
| Week 5 | $0.1752 | $0.2631 | $0.3952 | +1.99% |
| Week 6 | $0.1692 | $0.2642 | $0.4124 | +2.40% |
| Week 7 | $0.1639 | $0.2652 | $0.4291 | +2.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Vistagen Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on therapies for neuropsychiatric and neurological disorders. Its product pipeline includes Fasedienol, an investigational pherine nasal spray in Phase III for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational pherine nasal spray in Phase IIa to treat major depressive disorder.
It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray in Phase IIa for vasomotor symptoms, PH15 in Phase IIa to treat cognitive impairment caused by mental fatigue disorders, PH284 in Phase IIa for loss of appetite associated with chronic disorders, and AV-101, an oral prodrug targeting the NMDA receptor for depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders.
Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.
VTGN is a small-cap clinical-stage biotech with a focused neuropsychiatric/neurological portfolio and a collaboration footprint. The stock is currently priced at $0.2489 with a market capitalization of $10.21M and a market-rank of 4984. The 2026 forecast average is $0.2489, aligning with the present price and underscoring a potential flat baseline near the current level.
A major floor 10.9% below — a decisive break under it would weaken the trend.
The nearest floor, 10.9% below — buyers have tended to step in here.
The nearest ceiling, 194.6% above — a clean break opens room to run.
A major ceiling 266.9% above — clearing it would confirm fresh momentum.
Key VTGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VTGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.246 | Buy | $0.266 | Sell |
| MA 10 | $0.341 | Sell | $0.3301 | Sell |
| MA 20 | $0.4865 | Sell | $0.4222 | Sell |
| MA 50 | $0.5606 | Sell | $0.5304 | Sell |
| MA 100 | $0.5762 | Sell | $0.7514 | Sell |
| MA 200 | $1.64 | Sell | $1.28 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 32.44 | Neutral |
| Stoch RSI (14) | 10.98 | Buy |
| CCI (20) | -77.75 | Neutral |
| Williams %R (14) | -94.34 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -58.73 | Sell |
| Bollinger %B (20,2) | 0.22 | Neutral |
| Stochastic %K (14) | 5.66 | Buy |
| TRIX (15) | -1.58 | Sell |
| Awesome (5,34) | -0.29 | Sell |
| Ultimate (7,14,28) | 53.17 | Neutral |
| Momentum (10) | -0.36 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 0.22 | Buy |
| ADX (14) | 25.95 | Sell |
| ATR (14) | 0.04 | Info |
The 30-day technical picture shows neutral momentum, with RSI14 at 30. The price is trading below key moving averages, with SMA50 at $0.5946 and SMA200 at $1.71. The 30-day price range spans from $0.1506 to $0.4113, providing near-term support around $0.23 and resistance around $0.76.
Overall, near-term dynamics suggest limited upside unless new catalysts emerge.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.23 | $0.258 | $0.3867 | 0% | Neutral | |
| $0.2246 | $0.3096 | $0.4615 | +20% | Bullish | |
| $0.3753 | $0.5498 | $0.8732 | +113% | Bullish | |
| $0.3849 | $0.5939 | $0.9902 | +130% | Bullish | |
| $0.3424 | $0.5539 | $0.9614 | +115% | Bullish | |
| $0.3804 | $0.6431 | $1.16 | +149% | Bullish | |
| $0.3326 | $0.5865 | $1.09 | +127% | Bullish | |
| $0.3398 | $0.6241 | $1.19 | +142% | Bullish | |
| $0.4585 | $0.876 | $1.71 | +240% | Bullish | |
| $0.5212 | $1.03 | $2.07 | +301% | Bullish | |
| $0.5871 | $1.30 | $2.86 | +406% | Bullish | |
| $1.19 | $2.65 | $6.09 | +926% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.23 | $0.258 | $0.3384 | +0.00% |
| August 2026 | $0.2392 | $0.2898 | $0.3658 | +12.33% |
| September 2026 | $0.221 | $0.2716 | $0.35 | -6.28% |
| October 2026 | $0.2162 | $0.269 | $0.3527 | -0.96% |
| November 2026 | $0.2303 | $0.2895 | $0.3851 | +7.62% |
| December 2026 | $0.2261 | $0.2869 | $0.3867 | -0.89% |
Click any year to see its month-by-month VTGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect VTGN to range from $0.23 to $0.3867 through 2026. The $0.258 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The VTGN price prediction for 2027 points to an average of $0.3096 (low $0.2246, high $0.4615) — a potential gain of +20% on today's $0.258. Buyers look set to stay in control over this stretch.
In 2028, VTGN is projected to trade between $0.3753 and $0.8732, averaging $0.5498 — a potential gain of +113% from today's $0.258. That is up +78% on the projected 2027 average. Momentum favours further upside here.
Vistagen Therapeutics, Inc.'s 2029 outlook centres on $0.5939, within a $0.3849 to $0.9902 range. That is up +8% on the projected 2028 average. That marks a +130% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, VTGN could reach as high as $0.9614, with a base case around $0.5539 and support toward $0.3424 — roughly +115% from $0.258. Momentum favours further upside here.
Expect VTGN to range from $0.3804 to $1.16 through 2031. The $0.6431 average target implies a +149% move from current prices. That is up +16% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The VTGN price prediction for 2032 points to an average of $0.5865 (low $0.3326, high $1.09) — a potential gain of +127% on today's $0.258. Momentum favours further upside here.
In 2033, VTGN is projected to trade between $0.3398 and $1.19, averaging $0.6241 — a potential gain of +142% from today's $0.258. That is up +6% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Vistagen Therapeutics, Inc.'s 2034 outlook centres on $0.876, within a $0.4585 to $1.71 range. That is up +40% on the projected 2033 average. That marks a +240% change versus current levels. Momentum favours further upside here.
By 2035, VTGN could reach as high as $2.07, with a base case around $1.03 and support toward $0.5212 — roughly +301% from $0.258. Buyers look set to stay in control over this stretch.
Expect VTGN to range from $0.5871 to $2.86 through 2040. The $1.30 average target implies a +406% move from current prices. That is up +26% on the projected 2035 average. Momentum favours further upside here.
The VTGN price prediction for 2050 points to an average of $2.65 (low $1.19, high $6.09) — a potential gain of +926% on today's $0.258. Buyers look set to stay in control over this stretch.
Investing $1,000 in VTGN today (≈ 3,875.968992 VTGN) could be worth
$10,258.04
+$9,258.04 (+926%) by 2050 · US Dollar
Based on the average projected VTGN price of $2.65 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VTGNwould be worth at today's price.
$1,000 invested in VTGN on Jul 10, 2025 (≈ 411.522622 VTGN) would be worth
$106.17
-$893.83 (-89.4%) today · 0.11× · US Dollar
Based on a VTGN entry price of $2.43 vs. today's $0.258.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.25 | $1,032 | +3.2% |
| 1 month ago | $0.54 | $477.78 | -52.2% |
| 3 months ago | $0.56 | $460.71 | -53.9% |
| 6 months ago | $0.7 | $368.57 | -63.1% |
| 1 year ago | $2.43 | $106.17 | -89.4% |
| All time (5.0y) ago | $91.2 | $2.83 | -99.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VTGN forecast.
Our base-case forecast reaches $0.52 around 2028.
Implied market cap at $0.52: $21.34M
The multi-year forecast projects a bullish trajectory, with notable upside in the late 2020s and into the 2030s and beyond. The 2027 avg is $0.3101, with a 24.6% ROI, followed by 2028 avg $0.5477 (120% ROI) and 2029 avg $0.5748 (130.9% ROI). By 2030 the avg is $0.5464 with a 119.5% ROI, and the bullish path continues through 2031 (avg $0.6469, ROI 159.9%), 2032 (avg $0.5712, ROI 129.5%), 2033 (avg $0.624, ROI 150.7%), 2034 (avg $0.897, ROI 260.4%), and 2035 (avg $1.03, ROI 312.5%).
The forecast extends to 2040 with an avg of $1.35 (ROI 442%) and to 2050 with an avg of $2.64 (ROI 961.1%), all labeled Bullish. These figures illustrate a potential long-term appreciation, but they are estimates and not guarantees; outcomes depend on clinical progress, regulatory decisions, and broader market conditions. The pipeline includes several Phase II/III programs and a licensed collaboration with AffaMed, which could influence future development and commercialization timelines.
Tap a question to reveal the answer.
Avg price $0.5464; min $0.3374; max $0.9492; ROI 119.5%; sentiment BULLISH.
Forecasts show bullish sentiment beginning in 2027, with rising average prices and ROIs reaching up to 961.1% by 2050.
Yes. The forecast lists a max of $6.07 for 2050 with an associated ROI of 961.1%.
Current price is $0.2489 and market cap is $10.21M.
RSI14 is 30, sentiment is NEUTRAL. SMA50 is $0.5946 and SMA200 is $1.71. The 30-day range is $0.1506 to $0.4113, with support at $0.23 and resistance at $0.76.
Vistagen Therapeutics, Inc. Community Discussion
0Share your Vistagen Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.